United States
Pfizer’s Bourla is ‘cautiously optimistic’ on tariffs, says M&A is on the table
Bourla, M&A, Pfizer, United States, TNFRSF19 gene, Policy, tariffs
Thermo Fisher jumps on the US investment bandwagon with $2B in additional spending
United States, Investments, Manufacture, Martes pennanti, Science, development aspects, Thermo Fisher
Regeneron turns to CDMO Fujifilm to boost US manufacturing capacity
Regeneron, Manufacture, Fujifilm, CDMO, Biological Factors, Capacity, United States, Boost
Roche looks to expand and upgrade US research centers as part of $50B investment strategy in the country
Roche (company), Indiana, United States, Investments, expansion, Pennsylvania, Expanding, upgrade, Research Organization
UPDATE: With looming Trump tariffs, pharma companies demand changes to stay in EU
EU, Pharma, Industry, Transplant Registry Unified Management Program, Policy, Investments, United States, drug price
U.S. Biotechs Reveal Tariff Exposure as Trade Inquiry Signals Imminent Pharmaceutical Tariffs
U.S. biotech, pharmaceutical tariffs, Section 232 investigation, supply chain exposure, trade policy, import costs, reshoring manufacturing, drug pricing, global supply chain, pharmaceutical ingredients, regulatory impact
J&J brushes off tariff headwinds with raised forecast, oncology surge
J&J, United States, Sales – occupational activity, Neoplasms, Johnson and Johnson, Caplyta, Intra-Cellular Therapies, Raised, Increased, Growth, Projections and Predictions
Sandoz Challenges Amgen in Antitrust Lawsuit to Launch Enbrel Biosimilar in the U.S.
Sandoz, Amgen, Enbrel, Erelzi, antitrust, biosimilar, etanercept, patent thicket, U.S. market, rheumatoid arthritis, competition, biologics, FDA approval.
Novartis to invest $23B in manufacturing so ‘all key medicines’ can be made in the US
Novartis, United States, Investments, Manufacture, production, Biological Factors, Novartis
Global Pharmaceutical Stocks Plummet Amid Trump’s Imminent Tariff Threats
Pharmaceutical tariffs, global pharma stocks, Trump import tariffs, drug manufacturing, supply chain disruption, pharmaceutical trade war, U.S. pharma policy